NYSE · Biotech stocks database

QGEN — Qiagen N.V.

QGEN (Qiagen N.V.) stock: $50.31, $10.37B market cap, $839.0M cash, $11.18B EV, $11.90B fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

QIAGEN is a global provider of Sample to Insight solutions for molecular diagnostics, applied testing, and life sciences research, offering sample preparation, assay technologies, bioinformatics, and automation to customers in clinical healthcare and research.

Source: company website via company website

Share price

$50.31

Market cap

$10,367.6M

Cash

$839.0M

Enterprise value

$11,183.0M

Balance sheet

Cash	$839.0M
Debt	$1,654.4M
Net cash	-$815.4M
Enterprise value	$11,183.0M
Basic shares	206.1M shares
Fully diluted shares	236.6M shares
Fully diluted market cap	$11,904.5M
Cash per share	$4.07
Quarterly burn	+$163.6M generated

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common

216.9M

Pre-funded warrants

0.0M

Options

—

RSUs

—

Warrants

0.0M

Converts

19.7M

Conv preferred

0.0M

ESPP reserve

—

FDSO

236.6M

Cap table as of 2025-12-31.

Price history

Loading QGEN daily closes…

Loading price history…

Next catalyst

NEU-411 · Jan 12 - Feb 23 in 14 mo · Phase 2 · Parkinson Disease; Parkinson; Idiopathic Parkinson Disease

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23 in 14 mo	NEU-411	Phase 2	Parkinson Disease; Parkinson; Idiopathic Parkinson Disease	—
Oct 27 - Dec 8 in 24 mo	INCB161734	Phase 3	Solid Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06645236	Not disclosed	Recruiting	Sponsor	QGEN	—	Metastatic Colorectal Cancer (mCRC)	—
NCT06820060	Not disclosed	Active, not recruiting	Sponsor	QGEN	—	Meningitis; Encephalitis Infection	—
NCT06824129	Not disclosed	Active, not recruiting	Sponsor	QGEN	—	Complicated Urinary Tract Infection	—
NCT07522073	Phase 3	Recruiting	Collaborator	INCY	—	Solid Tumors	—
NCT06680830	Phase 2	Recruiting	Collaborator	Neuron23 Inc.	—	Parkinson Disease; Parkinson; Idiopathic Parkinson Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for QIAGEN Gaithersburg, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Casdin Capital	0	-360,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.

Subscribe to Compounding Ego

QGEN — Qiagen N.V. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Active clinical trials

Specialist fund holders

Latest news

QGEN — Qiagen N.V.